Entry into a Material Definitive Agreement

SEC Filing Summary: Ekso Bionics Holdings, Inc. (Form 8-K)

Business Context and Reporting Period

Date of Report: January 15, 2014
Company: Ekso Bionics Holdings, Inc. (formerly PN Med Group Inc.)
Event: Completion of a reverse merger with Ekso Bionics, Inc. and a concurrent private placement offering (PPO).
Business Change: The registrant discontinued its former business of distributing medical supplies in Chile. It now operates as Ekso Bionics, a developer of wearable robotic exoskeletons for medical, military, and industrial applications. The transaction is accounted for as a reverse merger, with Ekso Bionics, Inc. deemed the accounting acquirer.

Key Financial Metrics

Capital Raised (PPO): Gross proceeds of approximately $20.58 million from the sale of 20,580,000 Units (1 share + 1 warrant) at $1.00 per Unit. This included the conversion of $5.0 million in Bridge Notes.
Cash Position: Approximately $11.0 million in cash immediately following the closing, after paying transaction expenses of ~$2.3 million and repaying a $2.5 million senior note.
Historical Performance (Ekso Bionics):

  • Revenue (9 months ended Sept 30, 2013): $2.51 million (Medical Devices: $1.14M; Engineering Services: $1.38M).
  • Net Loss (9 months ended Sept 30, 2013): $9.09 million.
  • Accumulated Deficit (as of Sept 30, 2013): $35.23 million.
  • Working Capital Deficit (as of Sept 30, 2013): $4.4 million.
Debt: The $2.5 million Senior Note Payable was repaid in full. The $5.0 million Bridge Notes were converted into equity.

Material Changes vs. Prior Period

  • Corporate Structure: Changed from a shell company (PN Med Group) to an operating medical device company (Ekso Bionics Holdings).
  • Ownership: Pre-merger shareholders of PN Med Group surrendered 17.48 million shares in a split-off. Ekso Bionics shareholders received 42.6 million shares of the new common stock.
  • Management: Complete turnover of the Board of Directors and executive officers. Nathan Harding appointed CEO; Max Scheder-Bieschin appointed CFO.
  • Fiscal Year: Changed from a fiscal year ending March 31 to one ending December 31.
  • Accounting: Historical financial statements now reflect those of Ekso Bionics, Inc. rather than PN Med Group.

Guidance, Outlook, and Risks

Outlook: Management believes the net proceeds from the PPO are sufficient to fund operations for approximately 18 months. The company plans to spend ~$9.0 million on sales and marketing and ~$10.0 million on G&A and R&D over the next two years to penetrate the medical rehabilitation market.
Risks:

  • Liquidity: History of losses and negative cash flows raises substantial doubt about the ability to continue as a going concern without additional financing.
  • Regulatory: Products are Class I medical devices; reclassification to Class II or III could delay marketing and increase costs.
  • Market Acceptance: Limited operating history and reliance on clinical studies to prove efficacy for reimbursement.
  • Competition: Intense competition from companies with greater resources in the medical and military exoskeleton sectors.
Unusual Items: The filing includes a "going concern" qualification in the auditor's report for the historical Ekso Bionics financials.

Investor Verification Checklist

  • Cash Runway: Verify the actual cash balance post-closing and the burn rate to confirm the 18-month operational runway.
  • Revenue Recognition: Review the accounting policy for medical device sales, where revenue is deferred and amortized over a 3-year maintenance period.
  • Dilution: Assess the impact of outstanding warrants (approx. 24.6 million shares) and options (approx. 9.9 million shares) on future share count.
  • Intellectual Property: Confirm the status of patents co-owned with the University of California and the terms of the exclusive license agreements.
  • Debt Obligations: Confirm the full repayment of the Senior Note and the terms of any remaining contingent liabilities.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.